The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: Evidence for heterooligomerization

Molecular Brain Research

Volumn 80, Issue 1, 2000, Pages 63-74

  Elmhurst, Jennifer L ^a   Xie, Zhidong ^a   O'Dowd, Brian F ^a,b   George, Susan R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

D3nf; Dimers; Dopamine D3 receptor; Oligomers; Splice variant

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DOPAMINE; DOPAMINE 3 RECEPTOR; EMONAPRIDE; HALOPERIDOL; OLIGOMER; RADIOLIGAND; SPIPERONE; SULPIRIDE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INSECT; LIGAND BINDING; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

ALTERNATIVE SPLICING; ANIMALS; BACULOVIRIDAE; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC VECTORS; HUMANS; LIGANDS; MICROSCOPY, CONFOCAL; POLYMERS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP;

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0034233796     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00120-0     Document Type: Article

References (25)

1. Benkirane M., Jin D.-Y., Chun R.F., Koup R.A., Jeang K.-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. J. Biol. Chem. 272:1997;30603-30606.
2. Colley N.J., Cassill J.A., Baker E.K., Zuker C.S. Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. Proc. Natl. Acad. Sci. USA. 92:1995;3070-3074.
3. Fishburn C.S., Belleli D., David C., Carmon S., Fuchs S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem. 268:1993;5872-5878.
4. Freedman S.B., Patel S., Marwood R., Emms F., Seabrook G.R., Knowles M.R., McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. 268:1994;417-426.
5. Fukushima Y., Asano T., Saitoh T., Anai M., Funaki M., Ogihara T., Katagiri H., Matsuhashi N., Yazaki Y., Sugano K. Oligomer formation of histamine H2 receptors expressed in Sf9 and COS7 cells. FEBS Lett. 409:1997;283-286.
6. George S.R., Lee S.P., Varghese G., Zeman P.R., Seeman P., Ng G.Y.K., O'Dowd B.F. A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J. Biol. Chem. 273:1998;30244-30248.
7. Giros B., Martres M.-P., Pilon C., Sokoloff P., Schwartz J.-C. Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem. Biophys. Res. Commun. 176:1991;1584-1592.
8. Griffon N., Crocq M.-A., Pilon C., Martres M.P., Mayerova A., Uyanik G., Burgert E., Duval F., Macher J.P., Javoy-Agid F., Tamminga C.A., Schwartz J.-C., Sokoloff P. Dopamine D3 receptor gene: organization, transcript variants and polymorphism associated with schizophrenia. Am. J. Med. Gen. 67:1996;63-70.
9. Grosse R., Schoneberg T., Schultz G., Gudermann T. Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol. Endocrinol. 11:1997;1305-1318.
10. Hebert T.E., Moffett S., Morello J.-P., Loisel T.P., Bichet D.G., Barret C., Bouvier M. A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271:1996;16384-16392.
11. Liu K., Bergson C., Levenson R., Schmauss C. On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain. J. Biol. Chem. 269:1994;29220-29226.
12. MacKenzie R.G., VanLeeuwen D., Pugsley T.A., Shih Y.H., Demattos S., Tang L., Todd R.D., O'Malley K.L. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur. J. Pharmacol. 266:1994;79-85.
13. Nagai Y., Ueno S., Saeki Y., Soga F., Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 194:1993;368-374.
14. Ng G.Y.K., Mouillac B., George S.R., Caron M., Dennis M., Bouvier M., O'Dowd B.F. Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur. J. Pharmacol. 267:1994;7-19.
15. Ng G.Y.K., Varghese G., Chung H.T., Trogadis J., Seeman P., O'Dowd B.F., George S.R. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology. 138:1997;4199-4206.
16. Nimchinsky E.A., Hof P.R., Janssen W.G.M., Morrison J.H., Schmauss C. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. 272:1997;29229-29237.
17. Pagliusi S., Chollet-Daemerius A., Losberger C., Mills A., Kawashima E. Characterization of a novel exon within the D3 receptor gene giving rise to an mRNA isoform expressed in rat brain. Biochem. Biophys. Res. Commun. 194:1993;465-471.
18. Ross R.J.M., Esposito N., Shen X.Y., Von Laue S., Chew S.L., Dopson P.R.M., Postel-Vinay M.-C., Finidori J. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol. Endocrinol. 11:1997;265-273.
19. Schmauss C. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J. Neurosci. 16:1996;7902-7909.
20. Schmauss C., Haroutunian V., Davis K.L., Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. USA. 90:1993;8942-8946.
21. Schoneberg T., Liu J., Wess J. Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor. J. Biol. Chem. 270:1995;18000-18006.
22. Snyder L.A., Roberts J.L., Sealfon S.C. Alternative transcripts of the rat and human dopamine D3 receptor. Biochem. Biophys. Res. Commun. 180:1991;1031-1035.
23. Sokoloff P., Andrieux M., Besancon R., Pilon C., Martres M.-P., Giros B., Schwartz J.-C. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 225:1992;331-337.
24. Sokoloff P., Martres M.-P., Giros B., Bouthenet M.-L., Schwartz J.-C. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43:1992;659-666.
25. Zhu X., Wess J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry. 37:1998;15773-15784.